Korean English

Solasia Announces Launch of Darvias® in Japan

News provided by
Solasia Pharma K.K. Tokyo Stock Exchange 4597
Aug. 23, 2022 11:35
TOKYO--(Business Wire / Korea Newswire)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/

Website: http://www.solasia.co.jp/en/

Contact

Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
+81 3 5843 8046 (TOKYO)
info@solasia.co.jp

This news is a press release provided by Solasia Pharma K.K..

Solasia Pharma K.K. News Releases
솔라시아, 일본서 ‘다르비아스’ 출시
솔라시아 파마(Solasia Pharma K.K., 이하 솔라시아)(도쿄증권거래소: 4597, 본사: 일본 도쿄, 사장 겸 최고 경영자: 아라이 요시히로[Yoshihiro Arai])가 재발성·불응성 말초T세포림프종(Peripheral T-Cell Lymphoma, PTCL) 치료제인 유기비소(organoarsenic) 의약품 ‘다르비아스(DARVIAS®) 인젝션 135mg(SP-...
2022년 8월 23일 11:35
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been approved for relapsed or refractory Peripheral T-Ce...
2022년 6월 20일 16:30
More News
Health Pharmaceutical New Product Overseas
Solasia Pharma K.K.
Follow
News Releases RSS Feed Website

국내 최대 배포망으로 보도자료를 배포하세요

지금 시작하기